Sarepta Therapeutics’ (SRPT) “Underperform” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their underperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report released on Thursday,Benzinga reports.

Other equities analysts have also recently issued reports about the company. Barclays initiated coverage on Sarepta Therapeutics in a research note on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 target price for the company. Citigroup lifted their price target on shares of Sarepta Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research note on Tuesday, March 10th. Oppenheimer reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Wedbush decreased their price objective on shares of Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Finally, Loop Capital set a $25.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd. Nine equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have issued a Sell rating to the company. According to data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $32.30.

Sarepta Therapeutics Stock Down 7.9%

Shares of NASDAQ SRPT opened at $19.97 on Thursday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. Sarepta Therapeutics has a 1 year low of $10.41 and a 1 year high of $72.05. The stock’s 50-day simple moving average is $18.69 and its 200-day simple moving average is $20.01. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -2.37, a PEG ratio of 0.31 and a beta of 0.42.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The business had revenue of $442.93 million during the quarter, compared to analysts’ expectations of $390.95 million. During the same period in the prior year, the company posted $1.90 EPS. The company’s revenue for the quarter was down 32.7% on a year-over-year basis. As a group, equities analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In related news, Director Stephen Mayo sold 7,239 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the sale, the director owned 1,765 shares of the company’s stock, valued at $30,040.30. This represents a 80.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. Kestra Advisory Services LLC acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $25,000. iSAM Funds UK Ltd acquired a new position in Sarepta Therapeutics during the 3rd quarter valued at approximately $25,000. Ancora Advisors LLC boosted its position in Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the period. Byrne Asset Management LLC bought a new position in Sarepta Therapeutics during the 3rd quarter worth $33,000. Finally, Allworth Financial LP grew its stake in Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,721 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early siRNA Phase 1/2 data (SRP‑1001, SRP‑1003) impressed investors — strong target knockdown, safety and muscle delivery signals sparked the share rally and lifted sentiment on Sarepta. SRPT Stock Surges on Promising Early Results From siRNA Programs
• Positive Sentiment: Options flow has been very bullish — large volume of call purchases suggests traders are positioning for further upside or continued momentum. Investors Buy Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT)
• Positive Sentiment: At least one major shop (reported coverage) raised its price target after the data, which helped validate the clinical news and contributed to the rally. Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results
• Neutral Sentiment: Analyst consensus remains cautious/neutral overall — the stock’s average rating is a “Hold,” reflecting mixed views despite the clinical upside. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of “Hold” from Brokerages
• Neutral Sentiment: Valuation and longer‑term upside are being reassessed: several writeups model potential upside but note the one‑day rebound and remaining execution risks. Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results
• Negative Sentiment: Some sell/underperform stances persist — Citigroup raised its PT but kept a sell rating, and Needham reaffirmed underperform, highlighting continued skepticism among parts of the sell‑side. These views can cap rallies if the broader data set or guidance don’t follow through. Brokerage Notes (Citigroup/Needham)
• Negative Sentiment: Cautious takeaways from analysts/commentators emphasize the data are early and limited; some warn it’s too soon to extrapolate material commercial potential, which could lead to profit‑taking or volatility. Sarepta Therapeutics: It’s Too Early To Get Excited About siRNA Data

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.